GDF10 (Growth Differentiation Factor 10), also known as bone morphogenetic protein 3B (BMP3B), is a member of the TGF-β superfamily involved in regulating cellular processes such as differentiation, apoptosis, and tissue repair. It plays roles in neural plasticity, metabolic regulation, and organ development. GDF10 antibodies are immunological tools designed to detect, quantify, or inhibit GDF10 protein activity in research and therapeutic contexts. These antibodies are crucial for studying GDF10's function in diseases like stroke, Alzheimer’s disease, and fibrosis, where its expression is often dysregulated. For instance, GDF10 is upregulated after brain injury, promoting neural repair, while in cancer, it may suppress metastasis by modulating epithelial-mesenchymal transition. Researchers employ GDF10 antibodies in techniques such as Western blotting, immunohistochemistry, and ELISA to analyze protein expression patterns or track therapeutic responses. Both monoclonal and polyclonal variants exist, with specificity validated through knockout controls or blocking assays. Recent studies also explore GDF10's potential as a therapeutic target, particularly in neuroregeneration and metabolic disorders, driving demand for high-affinity, selective antibodies. However, challenges remain in minimizing cross-reactivity with homologous proteins like BMP3. Overall, GDF10 antibodies serve as vital reagents for unraveling the protein's multifaceted roles and advancing translational applications.